- Home
- ENX vs STTK Comparison
ENX vs STTK Comparison
Compare ENX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- STTK
- Stock Information
- Founded
- ENX 2002
- STTK 2016
- Country
- ENX United States
- STTK United States
- Employees
- ENX N/A
- STTK N/A
- Industry
- ENX Finance/Investors Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ENX Finance
- STTK Health Care
- Exchange
- ENX Nasdaq
- STTK Nasdaq
- Market Cap
- ENX 165.4M
- STTK 37.6M
- IPO Year
- ENX N/A
- STTK 2020
- Fundamental
- Price
- ENX $9.21
- STTK $0.83
- Analyst Decision
- ENX
- STTK Hold
- Analyst Count
- ENX 0
- STTK 4
- Target Price
- ENX N/A
- STTK $3.00
- AVG Volume (30 Days)
- ENX 25.4K
- STTK 480.9K
- Earning Date
- ENX 01-01-0001
- STTK 07-31-2025
- Dividend Yield
- ENX 3.94%
- STTK N/A
- EPS Growth
- ENX N/A
- STTK N/A
- EPS
- ENX 0.16
- STTK N/A
- Revenue
- ENX N/A
- STTK $4,606,000.00
- Revenue This Year
- ENX N/A
- STTK N/A
- Revenue Next Year
- ENX N/A
- STTK N/A
- P/E Ratio
- ENX $61.00
- STTK N/A
- Revenue Growth
- ENX N/A
- STTK 69.65
- 52 Week Low
- ENX $7.84
- STTK $0.69
- 52 Week High
- ENX $10.07
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- ENX 44.65
- STTK 38.86
- Support Level
- ENX $9.24
- STTK $0.75
- Resistance Level
- ENX $9.34
- STTK $0.85
- Average True Range (ATR)
- ENX 0.09
- STTK 0.09
- MACD
- ENX 0.00
- STTK -0.01
- Stochastic Oscillator
- ENX 26.09
- STTK 9.59
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.